Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

Starting soon · Phase 1

Conditions studied: Polio Immunity

In brief

The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).

Key facts

Study ID

NCT07688369

Run by

Serum Institute of India Pvt. Ltd.

People needed

36

Starts

2026-07-01

Expected to finish

2027-03-01

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

Where it is running

• Doherty Clinical Trials Limited — East Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.